top of page

USFDA's recent Guidance on Biologics: Ophthalmic Products & Development of (CAR) T Cell Products

Writer: Sharan MuruganSharan Murugan

1. Certain Ophthalmic Products: Policy Regarding Compliance With 21 CFR


This guidance is intended to provide information to applicants and manufacturers regarding compliance with the requirements in part 4 (21 CFR part 4) for ophthalmic drugs packaged with eyecups, eye droppers, or other dispensers.

FDA is issuing this guidance for immediate implementation and applies to products with pending applications, approved products, and products marketed pursuant to section 505G of the FD&C Act (21 U.S.C. 355h) without an approved application under section 505 of the FD&C Act (21 U.S.C. 355) (commonly referred to as over-the-counter (OTC) monograph drugs).


2. Considerations for the Development of Chimeric Antigen Receptor (CAR) T Cell Products

Chimeric antigen receptor (CAR) T cell products are human gene therapy products in which the T cell specificity is genetically modified to enable recognition of the desired target antigen for therapeutic purposes.


This draft guidance is intended to assist sponsors, including industry and academic sponsors, developing CAR T cell products and providing CAR T cell-specific recommendations regarding chemistry, manufacturing, and control (CMC), pharmacology and toxicology, and clinical study design. Also provides recommendations for analytical comparability studies for CAR T cell products


3. An Acceptable Circular of Information for the Use of Human Blood and Blood Components


This final guidance supersedes the guidance of the same title updated December 2017, and provides specific labeling instructions for the administration and use of blood and blood components intended for transfusion.


Also, this guide will assist you in complying with labeling requirements under 21 CFR 606.122. The requirements under 21 CFR 606.122 specify that a circular of information must be available for distribution with blood and blood components intended for transfusion.

Comments


I Sometimes Send Newsletters

Thanks for submitting!

  • LinkedIn
  • Facebook
  • Twitter
  • Instagram

DISCLAIMER

The views expressed in this publication do not necessarily reflect the views of any guidance of government, health authority, it's purely my understanding. This Blog/Web Site is made available by a regulatory professional, is for educational purposes only as well as to give you general information and a general understanding of the pharmaceutical regulations, and not to provide specific regulatory advice. By using this blog site you understand that there is no client relationship between you and the Blog/Web Site publisher. The Blog/Web Site should not be used as a substitute for competent pharma regulatory advice and you should discuss from an authenticated regulatory professional in your state.  We have made every reasonable effort to present accurate information on our website; however, we are not responsible for any of the results you experience while visiting our website and request to use official websites.

bottom of page